Trial Number



Cystic Fibrosis

Participant Age Range

18 years to 50 years

Participant Gender


Enrolling Participants



A Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citrate), administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis subjects

This is a two-part, randomized, double-blind, placebo-controlled, ascending-dose study to evaluate the safety and PK of AR-501, a gallium citrate solution for inhalation, in adult healthy volunteer (HV) subjects and CF subjects, and efficacy in CF subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design.

Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.